open access
Neutrophil gelatinase-associated lipocalin as a marker of acute renal failure in cancer patients treated with cisplatin
open access
Abstract
Cisplatin is a widely used chemotherapeutic agent in the treatment of solid tumours. Its main side effect, limiting the use of higher doses, is nephrotoxicity manifested by acute kidney injury (AKI). Monitoring of kidney function and AKI detection during the treatment with cisplatin requires a serial measurements of serum creatinine, with estimation of glomerular filtration rate. This method allows the detection of AKI with a 24–48 hour delay, when glomerular filtration rate is significantly decreased. Research conducted in recent years has indicated a group of potential so-called morphological markers of kidney damage that allow earlier detection of AKI, also with subclinical manifestation (without a significant increase in serum creatinine). This is following cardiac surgery and after administration of contrast agents. The best characterised of these markers is neutrophil gelatinase-associated lipocalin (NGAL). It is a protein physiologically existing in the granules of neutrophils, bone marrow, lung, stomach, small and large intestines, pancreas and kidney. Its expression increases in the course of renal epithelial damage. Studies have demonstrated the utility of NGAL assessed in both serum and urine in the diagnosis of ischemic AKI. So far, studies of cancer patients treated with cisplatin did not confirm the usefulness of NGAL determination in serum, but demonstrated that its urine measurements enable earlier diagnosis of AKI than the routine serum creatinine assessment. This paper is a systematic review of these studies.
Abstract
Cisplatin is a widely used chemotherapeutic agent in the treatment of solid tumours. Its main side effect, limiting the use of higher doses, is nephrotoxicity manifested by acute kidney injury (AKI). Monitoring of kidney function and AKI detection during the treatment with cisplatin requires a serial measurements of serum creatinine, with estimation of glomerular filtration rate. This method allows the detection of AKI with a 24–48 hour delay, when glomerular filtration rate is significantly decreased. Research conducted in recent years has indicated a group of potential so-called morphological markers of kidney damage that allow earlier detection of AKI, also with subclinical manifestation (without a significant increase in serum creatinine). This is following cardiac surgery and after administration of contrast agents. The best characterised of these markers is neutrophil gelatinase-associated lipocalin (NGAL). It is a protein physiologically existing in the granules of neutrophils, bone marrow, lung, stomach, small and large intestines, pancreas and kidney. Its expression increases in the course of renal epithelial damage. Studies have demonstrated the utility of NGAL assessed in both serum and urine in the diagnosis of ischemic AKI. So far, studies of cancer patients treated with cisplatin did not confirm the usefulness of NGAL determination in serum, but demonstrated that its urine measurements enable earlier diagnosis of AKI than the routine serum creatinine assessment. This paper is a systematic review of these studies.
About this articleTitle
Neutrophil gelatinase-associated lipocalin as a marker of acute renal failure in cancer patients treated with cisplatin
Journal
Nowotwory. Journal of Oncology
Issue
Article type
Review paper
Pages
160-166
Published online
2016-06-01
Page views
761
Article views/downloads
3051
DOI
Bibliographic record
Nowotwory. Journal of Oncology 2016;66(2):160-166.
Authors
Dawid Szumilas
Jerzy Wojnar
Jerzy Chudek